The rise of Ketamine therapy
Traditional antidepressants take several weeks or months to take effect; and are ineffective for 1/3 to 1/2 of depression patients. Research from top academic institutions now show that low doses of ketamine can alleviate the symptoms of depression even for patients who haven’t responded to other treatments, and within hours rather than weeks. What has been most exciting and promising to researchers is that the infusions are even helping 60-80% of treatment-resistant depression patients — these are the most difficult to treat patients who have not responded to any other medication or treatment.
Scientific progress gives new insights into the depressed brain
Stress and depression appear to grind down neurons and change the nature and structure of their connections. Ketamine’s potent and immediate antidepressant effect has been linked to its ability to rebuild and regrow these neuronal connections.
Chronic stress can damage brain structure and connectivity
Depression and stress over time damage the signaling structures between neurons. These signaling structures are like highways that must be rebuilt for a healthy brain; without these pathways, the neurotransmitters are unable to travel.
Ketamine becomes an unprecedented new tool to repair and restore the brain.
The ability of these neurons to grow and develop these connections his highly dependent on the neurotransmitter glutamate. Ketamine acts to regulate glutamate levels which strengthens these connections and restores them to a healthy, pre-stressed state.
The breakthrough that mental health has been waiting for.
The UpLift Me protocol is based on research from some of the most prestigious medical institutions in the world. Our patients have experienced rapid, significant relief after undergoing the six infusions within the protocol’s 20-day cycle.
"Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades."
-Dr. Thomas Insel
Former Director of the National Institute of Mental Health
A revolutionary new treatment arrives to address an urgent need
Depression is the leading cause of disability worldwide affecting over 300 million people, according to the World Health Organization.
Rates of depression, anxiety, suicide, and other measures of deteriorating mental health continue to rise at an alarming rate.
With no notable innovation in the treatment of depression over the past several decades, this new treatment and this new understanding of depression may be arriving when it is most needed.